Page 3 - Bo Cumbo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The combined company will focus on the advancement of neuromuscular and cardiac programs for the treatment of Duchenne muscular dystrophy.

BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

CAMBRIDGE, Mass. & GAINESVILLE, Fla., Oct. 12, 2021 -- AavantiBio, a gene therapy company focused on transforming the lives of patients with rare

AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases Share Article AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich�...

Auburn COSAM alum dedicated to curing diseases with new gene therapy venture Published: January 14, 2021 Decrease Font Size Font Size Increase Font Size Article body Auburn alum Bo Cumbo is dedicated to saving the world – by defeating one rare disease at a time. The 1994 laboratory technology graduate is busy building his newest gene therapy venture, AavantiBio, as he puts more than a quarter century of experience to work fighting rare or specialty diseases. Buoyed by $107 million in funding from private investors, industry leaders and former employers, Cumbo is unleashing ...